Mira Pharmaceuticals, Common Stock Performance
| MIRA Stock | 1.27 0.01 0.78% |
The company secures a Beta (Market Risk) of 0.0784, which conveys not very significant fluctuations relative to the market. As returns on the market increase, MIRA Pharmaceuticals,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding MIRA Pharmaceuticals, is expected to be smaller as well. At this point, MIRA Pharmaceuticals, has a negative expected return of -0.42%. Please make sure to verify MIRA Pharmaceuticals,'s day median price, period momentum indicator, as well as the relationship between the accumulation distribution and potential upside , to decide if MIRA Pharmaceuticals, performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days MIRA Pharmaceuticals, Common has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Vision Marine Technologies Announces Closing of Common Share Offering - Lexington Herald Leader | 09/16/2024 |
2 | This Warren Buffett Stock Just Hit Its Lowest Price In 2 Years. Why Isnt He Buying More - Barchart | 09/23/2024 |
3 | Mira Launches Menopause Transitions Kit to Help Women Prepare for Early Symptoms | 10/17/2024 |
4 | Miras journey of cultural connection and professional growth | 10/21/2024 |
5 | MIRA Pharmaceuticals Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain | 10/28/2024 |
6 | MIRA Continues Solid Financial Management | 11/13/2024 |
7 | Insider Trading | 11/18/2024 |
8 | Heres Why Were Not Too Worried About MIRA Pharmaceuticals Cash Burn Situation | 11/19/2024 |
9 | MIRA Reveals Innovative Phase IIIa Protocol Design and Selection of Clinical Trial Site | 11/20/2024 |
| Begin Period Cash Flow | 350.98 |
MIRA |
MIRA Pharmaceuticals, Relative Risk vs. Return Landscape
If you would invest 193.00 in MIRA Pharmaceuticals, Common on August 30, 2024 and sell it today you would lose (66.00) from holding MIRA Pharmaceuticals, Common or give up 34.2% of portfolio value over 90 days. MIRA Pharmaceuticals, Common is currently does not generate positive expected returns and assumes 7.1795% risk (volatility on return distribution) over the 90 days horizon. In different words, 63% of stocks are less volatile than MIRA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MIRA Pharmaceuticals, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MIRA Pharmaceuticals,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MIRA Pharmaceuticals, Common, and traders can use it to determine the average amount a MIRA Pharmaceuticals,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0587
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MIRA |
Estimated Market Risk
| 7.18 actual daily | 63 63% of assets are less volatile |
Expected Return
| -0.42 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average MIRA Pharmaceuticals, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MIRA Pharmaceuticals, by adding MIRA Pharmaceuticals, to a well-diversified portfolio.
MIRA Pharmaceuticals, Fundamentals Growth
MIRA Stock prices reflect investors' perceptions of the future prospects and financial health of MIRA Pharmaceuticals,, and MIRA Pharmaceuticals, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MIRA Stock performance.
| Return On Equity | -7.49 | ||||
| Return On Asset | -1.78 | ||||
| Current Valuation | 17.67 M | ||||
| Shares Outstanding | 16.56 M | ||||
| Price To Book | 5.93 X | ||||
| EBITDA | (3.46 M) | ||||
| Net Income | (11.98 K) | ||||
| Total Debt | 5.06 K | ||||
| Book Value Per Share | 0.30 X | ||||
| Cash Flow From Operations | (5.63 M) | ||||
| Earnings Per Share | (0.55) X | ||||
| Market Capitalization | 21.2 M | ||||
| Total Asset | 4.93 M | ||||
| Retained Earnings | (21.29 M) | ||||
| Working Capital | (875.63 K) | ||||
About MIRA Pharmaceuticals, Performance
By analyzing MIRA Pharmaceuticals,'s fundamental ratios, stakeholders can gain valuable insights into MIRA Pharmaceuticals,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MIRA Pharmaceuticals, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MIRA Pharmaceuticals, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.43) | (2.55) | |
| Return On Capital Employed | (1.95) | (1.85) | |
| Return On Assets | (2.43) | (2.55) | |
| Return On Equity | (2.74) | (2.60) |
Things to note about MIRA Pharmaceuticals, performance evaluation
Checking the ongoing alerts about MIRA Pharmaceuticals, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MIRA Pharmaceuticals, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MIRA Pharmaceuticals, generated a negative expected return over the last 90 days | |
| MIRA Pharmaceuticals, has high historical volatility and very poor performance | |
| MIRA Pharmaceuticals, may become a speculative penny stock | |
| MIRA Pharmaceuticals, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (11.98 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| MIRA Pharmaceuticals, generates negative cash flow from operations | |
| MIRA Pharmaceuticals, has a poor financial position based on the latest SEC disclosures | |
| About 27.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: MIRA Reveals Innovative Phase IIIa Protocol Design and Selection of Clinical Trial Site |
- Analyzing MIRA Pharmaceuticals,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MIRA Pharmaceuticals,'s stock is overvalued or undervalued compared to its peers.
- Examining MIRA Pharmaceuticals,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MIRA Pharmaceuticals,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of MIRA Pharmaceuticals,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MIRA Pharmaceuticals,'s stock. These opinions can provide insight into MIRA Pharmaceuticals,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for MIRA Stock analysis
When running MIRA Pharmaceuticals,'s price analysis, check to measure MIRA Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MIRA Pharmaceuticals, is operating at the current time. Most of MIRA Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of MIRA Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MIRA Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of MIRA Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |